SITE MAP

• AstraZeneca and Our Year In Brief
  • Financial highlights
  • Product performance summary
  • Dividend for 2007
• Chairman's Statement
• CEO review
  • Strengthening the pipeline
  • Valued medicines
  • Becoming lean and agile
  • Doing business the right way
  • Senior executive team changes
  • Looking ahead
• Directors' Report: Business Review
  • Goals, strategy and performance measurement
    • Performance
    • Reporting performance - Financial
    • Reporting performance - Non-financial
  • Business environment
    • Growing demand for healthcare
    • World markets
    • Biologics and vaccines
    • Therapy area environment
    • Challenges for the industry
  • Business organisation
    • AstraZeneca PLC Board composition, processes and responsibilities
    • R&D Executive Committee
    • Board of Directors
    • Chief Executive Officer, Delegation of Authority and Senior Executive Team
      
  • Our resources, skills and capabilities
    • Medicines
    • Research and development
    • R&D governance and portfolio management
    • Development pipeline
    • Sales and marketing
    • Intellectual property
    • Supply and manufacturing
    • People
    • Main facilities
  • Corporate governance and managing risk
    • Corporate governance: Operation of the Board of Directors
    • Corporate governance: Operation of Board Committees
    • Corporate governance: Principal UK and US governance requirements
    • Corporate governance: Other matters
    • Managing risk
• Directors' Report: Our Performance
  • Therapy area review
    • Cardiovascular medicines
    • Gastrointestinal medicines
    • Neuroscience medicines
    • Oncology medicines
    • Respiratory and Inflammation medicines
    • Infection medicines
    • Other businesses
  • Geographical review
    • Performance
    • North America
    • Rest of the World
  • In the global community
    • In the developing world
  • Environmental review
    • Climate change
    • Pharmaceuticals in the environment (PIE)
  • Financial review
    • Measuring performance
    • Business background and major events affecting 2007
    • Results of operations - summary analysis of year to 31 December 2007
    • Financial position, including cash flow and liquidity
    • Acquisition of MedImmune
    • Restructuring and synergy costs
    • Capitalisation and shareholder return
    • Future prospects
    • Financial risk management policies
    • Critical accounting policies and estimates
    • Off-balance sheet transactions, contingent liabilities and commitments
    • Post-employment benefits
    • International accounting transition
    • New accounting standards
    • Sarbanes-Oxley Act section 404
    • Results of operations - summary analysis of year to 31 December 2006
    • Financial position, including cash flow and liquidity - 2006
• Remuneration Report
  • Remuneration Committee membership and meetings
  • Remuneration Committee remit and key activities during the year
  • AstraZeneca's overall remuneration policy and purpose
  • Components of remuneration
  • Executive Directors' and the Senior Executive Team's remuneration and terms of employment
  • Audit
  • Directors' emoluments in 2007
  • Pensions
  • Transactions with Directors
  • Total shareholder return graphs
  • Directors' interests in shares
  • Share options
  • Gains by Directors on exercise of share options
• Financial Statements
  • Preparation of the Financial Statements and Directors' Responsibilities
  • Directors' Responsibilities for, and Report on, Internal Control over Financial Reporting
  • Auditors' Reports on the Financial Statements and on Internal Control over Financial Reporting (Sarbanes-Oxley Act Section 404)
  • Independent Auditors' Report to the Members of AstraZeneca PLC (Group)
  • Consolidated Income Statement
  • Consolidated Statement of Recognised Income and Expense
  • Consolidated Balance Sheet
  • Consolidated Cash Flow Statement
  • Accounting Policies (Group)
  • Notes to the Financial Statements (Group)
    • Notes 1-5
    • Notes 6-10
    • Notes 11-15
    • Notes 16-20
    • Notes 21-25
    • Notes 26-30
  • Principal Subsidiaries
  • Independent Auditors' Report to the Members of AstraZeneca PLC (Company)
  • Company Balance Sheet
  • Accounting Policies (Company)
  • Notes to the Financial Statements (Company)
    • Notes 1-5
    • Notes 6-9
  • Group financial record
• Additional information
  • Shareholder information
    • Percentage analysis at 31 December 2007 of issued share capital
    • AstraZeneca PLC
    • Major shareholdings
    • Related party transactions
    • Options to purchase securities from registrant or subsidiaries
    • Dividend payments
    • Shareview
    • ShareGift
    • The Unclaimed Assets Register
    • Results
    • Documents on display
    • Taxation for US residents
    • UK and US income taxation of dividends
      
    • Taxation on capital gains
    • Passive foreign investment company rules
    • UK inheritance tax
    • UK stamp duty reserve tax and stamp duty
    • Exchange controls and other limitations affecting security holders
    • Exchange rates
    • Definitions and interpretations
  • Risk
    • Risks associated with forward-looking statements
    • Industry/economic environment risks
    • Legal/compliance/regulatory risks
    • Business execution risks
    • Reputation
  • Corporate information
    • History and development of the company
    • Memorandum and articles of association
  • Cross-reference to Form 20-F
  • Glossary
    • A-E
    • F-M
    • N-T
    • U-Z
  • Contact information